NCT04721106 2026-02-10Korea Post Marketing Surveillance (PMS) Study of VizimproPfizerCompleted188 enrolled
NCT04155541 2025-05-23Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)PfizerCompleted40 enrolled
NCT04511533 2024-04-05Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsPfizerPhase 4 Completed101 enrolled 11 charts
NCT01774721 2023-11-14ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.PfizerPhase 3 Completed452 enrolled 35 charts 1 FDA
NCT00548093 2019-05-21PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And ErlotinibPfizerPhase 2 Completed66 enrolled 19 charts
NCT01858389 2017-07-18A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung CancerPfizerPhase 2 Completed41 enrolled 16 charts
NCT01121575 2015-10-28A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung CancerPfizerPhase 1 Completed70 enrolled 50 charts
NCT00769067 2015-10-07A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenPfizerPhase 2 Completed188 enrolled 14 charts
NCT00971191 2012-06-22A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804PfizerPhase 1 Terminated22 enrolled